AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating ABBV a “Buy” or “Strong Buy” and price targets suggesting further upside. Today’s Featured Stock Valued at $394 billion, AbbVie (ABBV) has become one of the top-most phar ...